NASDAQ$CGON
CG Oncology Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open
Briefing
CG Oncology reported Q4 2025, net loss of $41.3M, diluted EPS of $-0.52.
For Q4 2025, CG Oncology reported a net loss of $41.3M, diluted EPS was $-0.52. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Net loss $41.3M.
- Diluted EPS $-0.52.
- CG Oncology MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
CG Oncology Inc · Revenue · Quarterly
$1.16M
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks; numeric multi-quarter bridges vary by issuer.
Tailwinds
- MD&A highlights liquidity, capital, and core business trends.
- Segment or product commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure near-term margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q4 2025
+0.6%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+5.6%
Avg return
30 days after
63%
5 / 8 earnings
Positive
+8.6%
Q3 2025
Best reaction
-7.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +6.9% | -22.5% | |
| Q4 2025 | +4.8% | +9.7% | +15.2% | |
| Q3 2025 | +8.6% | +12.8% | +8.4% | |
| Q2 2025 | +2.1% | +8.8% | +35.8% | |
| Q1 2025 | -3.9% | +1.1% | +5.3% | |
| Q3 2024 | -6.8% | -17.1% | -27.3% | |
| Q2 2024 | +7.0% | +7.9% | +22.5% | |
| Q1 2024 | -7.4% | -15.8% | +7.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro